Cullen/Frost Bankers, Inc. Roivant Sciences Ltd. Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 8,300 shares of ROIV stock, worth $105,410. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,300
Previous 8,300
-0.0%
Holding current value
$105,410
Previous $87,000
9.2%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
311Shares Held
508MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$837 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$836 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$687 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$529 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$449 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.95B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...